Background: HIV controllers (HIC) are rare HIV-1-infected patients who exhibit spontaneous viral control. HIC have high frequency of CD38 2 /HLA-DR + HIV-specific CD8 + T cells. Here we examined the role of this subset in HIC status.
Introduction
A very small number of HIV-1-infected individuals spontaneously control viral replication. These so-called HIV controllers (HIC) usually have relatively high CD4 + T cell counts and remain AIDS-free for several decades [1, 2] . Several factors have been implicated in HIC status, including viral defects, cellular factors, and the innate immune system [3] , but T cells, especially HIVspecific CD8 + T cells, are considered to play a major role. Overrepresentation of certain HLA class I alleles (especially HLA-B*57 and HLA-B*27) is associated with strong HIV-specific CD8 + T cell responses [4] [5] [6] . Studies of simian disease models also show that expression of the MHC class I alleles Mamu-B*08 and Mamu-B*17 correlates with viral control [7, 8] . Several studies have linked viral control to HIV-specific CD8 + T cell polyfunctionality [9] , proliferation to HIV antigens, and lytic granule content [10, 11] .
We and others have shown that HIC usually possess HIVspecific CD8
+ T cells capable of suppressing HIV replication ex vivo [12, 13] . Although HIV-specific CD8 + T cells usually express similar levels of two activation markers -CD38 and HLA-DRwhich correlate with viral load in non-controllers [14] , they exhibit a peculiar activation phenotype in HIC, with low CD38 expression and high HLA-DR expression [13, 15] . Immune activation can have opposite effects on CD8 + T cell functional capacities. Indeed, a degree of immune activation is necessary for efficient effector responses (resting CD8 + T cells usually lack effector functions but can become cytotoxic when activated [16] ), whereas overactivation may lead to exhaustion [17] and functional inefficiency [18] . The CD38 2 /HLA-DR + phenotype might reflect a low level of activation and could thereby contribute to HIC status [13, 15, 19] .
Here we studied CD38 2 /HLA-DR + HIV-specific CD8 + T cells in a large population of HIC, focusing on functional activation status, memory/effector functions, and the mechanism underlying HLA-DR expression in the absence of CD38 expression.
Materials and Methods

Ethics statement
All the subjects provided their written informed consent to participation. The study was approved by the local investigational review board (Comité de Protection des Personnes Ile de France VII, Paris, France) and performed in accordance with the tenets of the Declaration of Helsinki.
Study participants
We collected samples from 120 HIV-infected individuals, comprising 80 patients enrolled in the French ANRS CO21 CODEX cohort of HIC (inclusion criteria: HIV infection at least 5 years previously; 5 latest plasma HIV RNA values ,400 copies/ mL; no HAART), 21 untreated, chronically viremic patients, and 19 HAART-treated aviremic individuals (HIV RNA ,50 copies/ mL) enrolled in the French ANRS CO6 PRIMO cohort. Clinical and biological characteristics of the study participants are shown in Table 1 . Peripheral blood samples from seven HIV-uninfected healthy blood donors (HD) were obtained from Etablissement Français du Sang (Paris, France).
Cell preparation
Peripheral blood mononuclear cells (PBMC) were isolated from EDTA-anticoagulated blood by Ficoll density gradient centrifugation and stored in liquid nitrogen. Human leukocyte antigen typing used the complement-dependent microlymphocytotoxic technique (Ingen).
Flow cytometry of HIV-specific CD8
+ T cells
Specific CD8
+ T cells were characterized by staining, first for 15 minutes at room temperature with APC-labeled peptide-HLA class I multimers (Proimmune and Immudex for HLA-B*57 peptides) derived from the HIV proteins Gag, Nef, Pol, and Env and from the Epstein-Barr virus (EBV) proteins BMLF-1 and BZLF-1, and then with labeled antibodies for 15 minutes at 4uC. Anti-CD38-PerCP-Cy5.5 and anti-HLA-DR-PE-Cy7 were used to identify and sort the different activation subsets. The following antibodies were used to characterized HIV-specific CD8 + T cells: FITC-coupled anti-CD71, -CD40, -Bcl-2 and -Granzyme B; PEcoupled anti-Ki67, -CD69 and -CD25; V450-coupled anti-CD8 (BD Biosciences); VioGreen-coupled anti-CD3 (Miltenyi Biotec); and PE-coupled anti-perforin (clone D48, Diaclone). Dead cells were excluded by using the Live Dead Fixable Near-IR Dead Cell Stain kit (Molecular Probes, Invitrogen). For intracellular staining, cells were incubated with the appropriate antibodies for 30 minutes at 4uC after incubation with FACS permeabilizing solution (BD Biosciences). Samples were acquired on an LSR Fortessa cell analyzer (BD Biosciences) and analyzed with FACS DIVA software (BD Biosciences). An example of the gating strategy is shown in the Figure S1 and an example of the expression of the activation markers and cytokine production by the different subsets is shown in Figure S2 . We assessed an average of two tetramers per patient and acquired at least 80 events per subset studied.
CD8 + T cells were sorted with an ARIA cell sorter (BD Biosciences) into the following activation subsets: CD38 2 /HLA-DR
+ /HLA-DR 2 , and CD38 + /HLA-DR + , using anti-CD56-PE to exclude NK cells, anti-CD8-V450 and anti-CD4-APC-H7 antibodies (BD Biosciences) according to the manufacturer's guidelines. After sorting, cells were resuspended at a density of 1610 6 /mL and cultured for five days before used in the cytotoxicity assay described below. Purity was routinely .95% for each subset (data not shown). Too few cells expressed the CD38 + / HLA-DR 2 phenotype to obtain interpretable data.
Intracellular cytokine production
PBMC were stimulated for 15 hours in medium containing the relevant optimal HIV peptide (2 mM). After 1 hour of stimulation, cytokine secretion was blocked by adding brefeldin A (10 mg/mL, Sigma-Aldrich Chemie). After further incubation, samples were stained as described above. Anti-IFN-c-APC and anti-IL-2-PE antibodies (BD Biosciences) were used to detect intracellular cytokine production. A negative control (medium) and a positive control (staphylococcal enterotoxin B, SEB) were included in each experiment. The polyfunctionality was assessed by measuring the dual production of IFN-c and IL-2. The results were expressed as frequency of IFN-c + /IL-2 + producing cells among IFN-c + or IL-2 + producing cells.
In vitro HIV suppression assay
The capacity of CD8 + T cells to suppress HIV-1 infection of autologous CD4 + T cells ex vivo was assessed as described in details elsewhere [20] . Briefly, CD4 + T cells were activated with phytohemagglutinin (PHA) and IL-2 for three days, then infected with HIV-1 BaL and cultured alone or with unstimulated autologous CD8 + T cells (1:1 ratio). P24 antigen was measured in culture supernatants with an ELISA method (Zeptometrix) as a measure of viral replication. The capacity of CD8 + T cells to suppress HIV infection was expressed as the log decrease in p24 production when superinfected CD4 + T cells were cultured in the presence of CD8 + T cells.
Cytotoxicity assay
The Grantoxilux Plus! cytotoxicity assay was used according to the manufacturer's instructions (OncoImmunin, Inc). It is based on Granzyme-B-mediated intracellular cleavage of a fluorogenic substrate in live target cells. Briefly, PBMC were used as target cells, CD8
+ T cells as effectors, and CD8-depleted PBMC as feeders. Target cells were stimulated with PHA and IL-2 for five days. Effector cells were cocultured with feeders at a ratio of 1:1 and with HIV peptide (2 mM) for five days. On day 5, target cells were primed for 1 h with the cognate or an irrelevant peptide, labeled with TFL4 (OncoImmunin, Inc.), and then cocultured with CD8
+ T cells at an Effector:Target ratio of 50:1. The cells were then incubated with Granzyme B substrate (OncoImmunin Inc.) for 1 h and analyzed immediately by flow cytometry. The results are expressed as the difference between the frequency of lysed target cells incubated with the cognate peptide and the frequency of lysed target cells incubated with the irrelevant peptide. An example of the cytotoxic assay is shown in Figure S3 .
Healthy donor cell culture
CD8
+ T cells were isolated by using a human anti-CD56 antibody (Miltenyi Biotec) to deplete NK cells and a human anti-CD8 antibody (Miltenyi Biotec). Purity was greater than 95%.
Isolated CD8
+ T cells were cultured in vitro (2610 6 cells/mL) with medium alone, with the optimal concentrations of peptides, or with anti-CD3/CD28 antibodies as control (Miltenyi Biotec). IFNa (PBL InterferonSource) was used at 500 IU/mL.
Functional avidity
Functional avidity was measured in an IFN-c ELISpot assay using single-epitope peptides corresponding to optimal HIV-CTL epitopes (National Institutes of Health HIV Molecular Immunology Database: http://www.hiv.lanl.gov/content/immunology/ tables/optimal_ctl_ summary.html) according to the subjects' HLA types. Functional avidity of CD8 + T cell responses was assessed by performing limiting peptide dilutions ranging from 10 25 to 10 211 M in in vitro assays as described elsewhere [21] . It was defined as the peptide concentration required to achieve 50% of the maximal response (EC 50% ) and was expressed as log EC 50% .
Statistical methods
Data were analyzed with Prism software (GraphPad Software Inc.). Groups were compared using a nonparametric MannWhitney or Wilcoxon paired test for continuous data or a chisquared test for categorical data. Correlations were evaluated using Spearman's rank correlation coefficient. The Spearman r correlation and (in the Figures) the Pearson correlation curve are indicated for significant correlations. The threshold for statistical significance was set to P,0.05.
Results
Study population
Baseline data for the 80 HIC, 21 viremic patients and 19 HAART-treated patients are shown in Table 1 . HIC differed significantly from the other two groups of patients in terms of the sex ratio, age, CD4
+ and CD8 + T cell counts, viral RNA loads, and time since diagnosis.
Higher frequencies of CD38
2 /HLA-DR + HIV-specific CD8 +
T cells in HIV controllers
We first compared CD38 and HLA-DR expression ex vivo on bulk CD8
+ T cells in the healthy donors (HD), viremic patients, HAART-treated patients, and HIV controllers (HIC) ( Figure 1A -B) and on HIV-specific CD8 + T cells in the three groups of HIVinfected patients ( Figure 1C-D Fig. 3A) .
We then analyzed dual production in vitro of IFN-c and IL-2 as a marker of polyfunctionality. As shown in Figure 3B Although ex vivo perforin expression did not differ between the two subsets (52% [21%-67%] and 52% [26%-67%], respectively, P = 0.26, Fig. 3D + /HLA-DR + counterparts. Ex vivo HIV-suppressive activity was routinely evaluated with freshly isolated whole-blood T cells which often include several HIV specificities while cytotoxicity was evaluated only on immunodominant peptides. Of note, HIV-specific CD8 + T cell cytotoxicity correlated with HIV-suppressive activity, expressed as the log decline in p24 antigen (P = 0.004; r = 0.37, data not We postulated that the CD38 + /HLA-DR + profile might result from a dual activation pathway, in which antigenic peptide stimulation leads to HLA-DR expression while indirect activation by IFN-a leads to CD38 expression [22, 23] . As expected, IFN-a stimulation led to CD38 expression on bulk CD8
+ T cells (14% [7%-17%]) and, to a lesser degree, on EBV-specific CD8 + T cells (9% [4%-28%]), whereas neither bulk nor EBV-specific CD8 + T cells expressed HLA-DR (0% [0%-1%] and 0% [0%-1%] respectively; Figure 4 , middle panel), confirming the non-specific nature of IFN-a-induced activation. However, stimulation with EBV peptides led to strong expression of both CD38 and HLA-DR by EBV-specific cells (69% [53%-84%] vs 72% [61%-83%], respectively; Figure 4 lower panel), while no change was observed in the total CD8 + T cell population. We suspected that the increase in CD38 expression might be related to IFN-a production by non T cells in this model, but neither blockade with an anti-IFN-aR antibody nor the use of highly purified CD8 + T cells significantly modified our results.
Interestingly, the antigen concentration correlated positively with the degree of activation and also affected the profile of activated cells. At low antigen levels, most activated cells expressed HLA-DR but not CD38. Indeed, the frequency of CD38 The CD38 2 /HLA-DR + phenotype by specific CD8 + T cells in HIC is conditioned by low viral loads and high antigen sensitivity
HIV-specific CD8
+ T cell sensitivity to cognate antigen, measured with an ELISpot assay, showed an overall positive correlation between the frequency of ex vivo CD38 2 /HLA-DR + in these cells and the antigen sensitivity of HIV-specific CD8 + T cells (r = 0.34, P = 0.01, Figure 6A ), whereas no such correlation was seen with CD38 2 /HLA-DR 2 cells (P = 0.39) or CD38 + /HLA-DR + cells (P = 0.05, Figure 6B ). These results suggest strongly that the CD38 2 /HLA-DR + subset is induced in the context of low viral loads and expressed on highly avid cells.
Discussion
HIV-specific CD8 + T cells in HIV controllers were initially shown to exhibit (i) efficient proliferation and cytotoxicity [10, 11] , (ii) strong virus suppression ex vivo [13] , and (iii) a particular activation phenotype: CD38 2 /HLA-DR + [13, 15] . Little is known about this CD8 + T cell subset and its possible role in HIC. The activation status of this CD38
2 /HLA-DR + subset in HIC is puzzling, as HLA-DR expression suggests an activated state, while the lack of CD38 expression suggests the opposite. None of the other activation markers studied here were expressed by these cells, including those expressed early after activation, such as CD69 and CD25, and those expressed later, such as CD71 and CD40 [24, 25] . This exclusive HLA-DR expression suggests a low state of activation, and is in keeping with absent expression of Ki-67, a marker of cell cycling. A previous study showed coexpression of HLA-DR and Ki-67 by these cells after immunotherapy, but the authors did not evaluate CD38 expression [26] .
This low level of activation is compatible with efficient survival evaluated here in terms of Bcl-2 expression level, and also with good proliferative potential. Previous studies showed an association between HLA-DR expression and proliferation [26, 27] . And indeed, these CD38 2 /HLA-DR + cells expanded 3-fold in culture, whereas their CD38 + /HLA-DR + counterparts did not expand significantly. Of note, this expansion of CD38 2 /HLA-DR + cells was associated with differentiation into effector cells, as their HIVspecific cytotoxicity was higher than that of CD38 + /HLA-DR + cells, even after adjusting for the HIV-specific-effector-to-target ratio. These data confirm those reported by Blankson et al., who showed that sorted CD38 2 /HLA-DR + CD8 + T cells from HIC, when placed in short-term culture with autologous unstimulated CD4 + T cells, were the first cells to suppress viral replication [28] . Additionally, although CD38
2 /HLA-DR + and CD38 + /HLA-DR + showed similar ex vivo cytotoxic capacity, the very low frequency of CD38 + /HLA-DR + cells, and their poor proliferative capacity shown here and elsewhere [29] , make it unlikely that this population has a major role in suppressing viral replication. These data suggest that in vivo CD38 2 /HLA-DR + cells which are less susceptible than CD38 + /HLA-DR + cells to exhaustion, have a greater capacity to control viral replication than CD38 + /HLA-DR + cells. Although we and others have observed that HIVspecific CD8 + T cells from some HIC patients lack HIVsuppressive activity ex vivo, they are capable of differentiating when exposed to cognate antigens, acquiring the ability to lyse infected cells and to suppress HIV replication [30] .
We also explored the conditions in which the CD38 2 /HLA-DR + phenotype is generated by using an in vitro model with EBV peptides and cells from healthy donors. We needed a nonactivated condition to evaluate the mechanism of CD38 and HLA-DR expression. EBV infection is a model of infection with effective memory resting cells while HIV infection leads to persistent activation and inflammation even in HIC. Therefore, we believed that the EBV-model is a more appropriate model to address the question of CD38 and HLA-DR induction after activation. We confirmed that IFN-a induces CD38 expression but not HLA-DR expression [22, 23] and that this activation is not virus-specific. Conversely, EBV peptide stimulation led to activation of EBVspecific CD8 + T cells expressing both CD38 and HLA-DR. It has been shown that strong TCR stimulation by anti-CD3/CD28 leads to cd38 transcription in purified CD8 + T cells [23] , possibly explaining how CD38 is expressed following peptide stimulation even in IFN-aR-antagonizing conditions. However, we found that low EBV peptide concentrations elicited the CD38 2 /HLA-DR + phenotype on the vast majority of activated cells, in keeping with the low viral load and lack of IFN-a production in experimental models of viral control [31] . Although plasmacytoid dendritic cells from HIC are able to produce IFN-a efficiently after HIV antigen stimulation in vitro [32, 33] , HIC do not produce detectable IFN-a in vivo, as shown by tissue studies [34] , which can explain the absence of IFN-a pathway mediated CD38 expression. The discrepancy between the low frequency of CD38 2 /HLA-DR + cells among virus-specific CD8 + T cells in our in vitro model and the high frequency observed in vivo in HIC may be due to the contrast between brief activation in vitro and chronic activation by low HIV viral loads in HIC. The preferential activation of the CD38 2 /HLA-DR + subset by low antigen concentrations is particularly interesting, as memory cells activated by low antigen concentrations show little senescence, have high proliferation 2 /HLA-DR + HIV-Specific CD8 + T Cells in HIC rates, are able to persist for long periods [35] , and maintain their TCR on the membrane surface, enabling a persistent cytotoxic response [36] . Furthermore, the peptide concentrations that yielded the CD38 2 /HLA-DR + phenotype in our in vitro EBV model are similar to the estimated concentrations of HIV antigens present in vivo [37, 38] . In addition, the high antigen sensitivity observed in HIC may reinforce preferential induction of the CD38 2 /HLA-DR + profile on the most sensitive cells, which are endowed with the best functional profile [21, [38] [39] [40] . Indeed, antigen sensitivity has been shown to correlate negatively with HIV cellular viral load [40] . However, high antigen sensitivity is not the only feature that can explain HIC status. Indeed, we observed no increase in the frequency of CD38 2 /HLA-DR + cells in patients positive for HLA-B*27 or HLA-B*57 ( [21] and data not shown) whereas antigen sensitivity is particularly high in this context [21, 39] . We moreover observed no difference in the frequency of this subset when comparing different HIV peptide specificities (data not shown). In addition, we have previously reported a lack of difference in perforin expression and inhibition of viral replication between HIC with and without protective HLA alleles [21, 41] .
T cell activation is necessary for effector functions such as cytotoxicity and suppression of viral replication, but the persistent immune activation associated with systemic inflammation is known to play a key role in HIV disease progression [42, 43] . This is also the case in HIC, who display low but higher frequencies of classical activated CD38 + /HLA-DR + CD8 + T cells than do healthy donors (HD) and HAART-treated patients [43] . This excessive immune activation may result from the persistence of extremely low levels of HIV replication [44] and/or enhanced microbial translocation from the gut [45] . HIC exhibit a degree of disease progression and sometimes experience a decline in CD4 + T cells or even lose their ability to control HIV [46] , possibly as a result of persistent immune activation [46, 47] . Alternatively, CD4 + T cell activation might permit persistent low-level infection of these cells, in turn maintaining efficient stimulation of the HIVspecific immune response [21, 43] and thereby helping to control viral replication through inducing CD38 2 /HLA-DR + profile.
Conclusions
The paradoxical activation profile of some HIV-specific CD8 + T cells, with HLA-DR but not CD38 expression and weak expression of all other activation markers, might confer the capacity to differentiate into effective cytotoxic cells after moderate activation [28] while avoiding the deleterious effects of excessive immune activation. It would be a favorable condition as compared to HAART-treated patients who display a very low viral load which leads to an absence of immune activation and effective response and as compared to viremic patients who display high viral load which leads to excessive activation and exhaustion. A high frequency of CD38 2 /HLA-DR + cells among total CD8 + T cells has been linked to slow HIV disease progression and high CD4 + T cell counts [48] . We suspect that the expansion of this particular activated subset will lead to effective HIV-specific CD8 + T cells capable of rapid viral suppression. Induction of this protective cell subset by activation with low concentrations of HIV antigens, together with limited lymphocyte activation, might have implications for HIV vaccine strategies. 
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